Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-16
2006-05-16
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S217060, C514S228200, C514S234200, C514S252170, C514S266200, C544S060000, C544S116000, C544S284000
Reexamination Certificate
active
07045526
ABSTRACT:
The present invention relates to compounds of formula I:wherein R1, R2, and R3have the meanings indicated in the specification, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases such as cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses, or atherosclerosis. Compounds of formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for the preparation of compounds of formula I, methods of therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, and pharmaceutical compositions which comprise at least one compound of formula I.
REFERENCES:
patent: 3322759 (1967-05-01), Carney et al.
patent: 3346452 (1967-10-01), Carney et al.
patent: 4306065 (1981-12-01), Chen
patent: 4610984 (1986-09-01), Schonafinger et al.
patent: 5250530 (1993-10-01), Giencke et al.
patent: 5436233 (1995-07-01), Lee et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 6245760 (2001-06-01), He et al.
patent: 40 29 654 (1992-04-01), None
patent: 407899 (1991-01-01), None
patent: 0 407 899 (1991-07-01), None
patent: 0 579 496 (1994-01-01), None
patent: 579496 (1994-01-01), None
patent: 579496 (1994-01-01), None
patent: 0 667 345 (1995-08-01), None
patent: 0 826 673 (1998-03-01), None
patent: 826673 (1998-03-01), None
patent: 7-228573 (1995-08-01), None
patent: 10-87492 (1998-04-01), None
patent: 10-130150 (1998-05-01), None
patent: WO 96/32383 (1996-10-01), None
patent: WO 97/47601 (1997-12-01), None
patent: WO 98/16223 (1998-04-01), None
patent: WO 98/16507 (1998-04-01), None
patent: 2000046214 (1999-05-01), None
patent: WO 00/09496 (2000-02-01), None
patent: WO 00/31047 (2000-06-01), None
patent: WO 00/48214 (2000-08-01), None
Cecil's Book of Medicine, vol. 2, 20thEdition, pp. 1992-1996(1996).
Coyle et al, Science vol. 219, 1184-90(1983).
Bischoff et al, Pub/Med Abstract 12597982, also cited as Urology, 61/2, 464-7(2003).
Arnavaz et al, PubMed Abstract 12694895, also cited as Psychiatry Res. 122/3,207-9(2003).
Conti et al, PubMed Abstract 10078540, also cited as Am. J. Cardiol. 83/5A, 29C-34C(1999).
Lee et al. J. Med. Chem. 38/18,3547-57(1995).
Albrecht et. al., Chemical Abstracts, vol. 86, Abstract#29739, 1977.
Abstract: DE 40 29 654 A1—P. Braun, K. Minn, B. Sachse, and H. Wicke, “New 2-phenyl-pyrimidine derivations—useful as plant protectants, especially fungicides,” Derwent Abstract No. 92-115248/199215.
Abstract: 07-228573—Yoshiaki Ochi, “2-Phenylcycloalkanopyrimidine Derivative,” European Patent Office Abstract.
Louis J. Ignarro, “Regulation of Cytosolic Guanylyl Cyclase by Porphyrins and Metalloporphyrins,”Advances in Pharmacology, vol. 26: 35-65 (1994).
Feng-Nien Ko, Chin-Chung Wu, Sheng-Chu Kuo, Fang-Yu Lee, and Che-Ming Teng,“YC-1, a Novel Activator of Platelet Guanylate Cyclase,”Blood, vol. 84 (12), 4226-4233 (Dec. 15, 1994).
Douglas J. Pettibone, Charles S. Sweet, Edwin A. Risley and Thomas Kennedy, “A Structurally Novel Stimulator of Guanylate Cyclase with Long-Lasting Hypotensive Activity in the Dog,”European Journal of Pharmacology, vol. 116: 307-312 (1985).
D. L. Vesely, “B complex vitamins activate rat guanylate cyclase and increase cyclic GMP levels,”European Journal of Clinical Investigation, vol. 15: 258-262 (1985).
David L. Vesely, “Phencyclidine Stimulates Guanylate Cyclase Activity,”Biochemical and Biophysical Research Communications, vol. 88(4): 1244-1248 (Jun. 27, 1979).
Chin-Chung Wu, Feng-Nien Ko, Sheng-Chu Kuo, Fang-Yu Lee, and Che-Ming Teng, “YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase,”British Journal of Pharmacology, vol. 116: 1973-1978 (1995).
Sheu-Meei Yu and Sheng-Chu Kuo, “Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta,”British Journal of Pharmacology, vol. 114: 1587-1594 (1995).
Sheu M. Yu, Zhi J. Chen, Jih H. Guh, Fang Y. Lee, and Sheng C. Kuo, “Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells,”Biochem J., vol. 306:787-792 (1995).
Abstract: JP 07 228573 A—Masahiro Kataoka, Katsuhiko Hino, and Yoshiaki Ochi, “Preparation of 2-phenylcycloalkanopyrimidine derivatives as antagonists of serotonin 8, receptor,”Chemical Abstracts, Columbus, Ohio, vol. 124, 87634q, 1996.
Abstract: JP 10 130150 A—Akiya Murata, Katsuhiko Hino, Kiyoshi Furukawa, Makoto Oka, and Mari Ito, “Preparation of acetic acid amide derivatives as drugs,”Chemical Abstracts, Columbus, Ohio, vol. 129, 54385e, 1998.
International Search Report mailed May 29, 2000.
Abstract: Honda, I. et al., “Synthesis and Dimroth Rearrangement of 2,4-bis(2-hydroxy-1-cycloalkenyl)-1,3,5-triazines,” Fukui Daigaku Kogakubu Kenkyu Hokoku 36/2, 165-81 (1988).
Liddendirff et al., “Multiple Roles of the Messenger Molecule cGMP in Testicular Function,” Andrologia, 32/1, 55-59 (2000).
Schindler Ursula
Schönafinger Karl
Strobel Hartmut
Sanofi-Aventis Deutschland GmbH
Truong Tamthom N.
LandOfFree
Substituted 4-amino-2-aryl-tetrahydroquinazolines, their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 4-amino-2-aryl-tetrahydroquinazolines, their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 4-amino-2-aryl-tetrahydroquinazolines, their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3547630